Trial Profile

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab govitecan (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Proof of concept; Therapeutic Use
Acronyms Tropics-03
Sponsors Gilead Sciences; Immunomedics

Most Recent Events

30 Jan 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
20 Oct 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.
03 Mar 2025 Planned End Date changed from 1 Mar 2025 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com